| Autor: |
Hymøller SH; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark., Kaaber IA; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark., Lesbo M; Department of Orthopedic Surgery, Regional Hospital Viborg, Viborg, Denmark., Borris LC; Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark., Brink O; Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark., Møller HJ; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark., Hviid CVB; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark.; Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark. |
| Abstrakt: |
Soluble CD163 (sCD163) is a biomarker of macrophage activation, not previously investigated in the circulation of traumatized patients. A biobank of 398 adult trauma patients was analyzed. Patients with an Injury Severity Score (ISS) >8 served as trauma patients ( n = 195) and those with ISS ≤ 8 as trauma controls ( n = 203). Serum samples obtained upon admission, 15h and 72h after were analyzed for sCD163 using an in-house ELISA. Multiple linear regression was used to analyze the association between admission levels of sCD163 with, 1: overall trauma severity (ISS), and 2: severity of injury to specified organs using Abbreviated Injury Score (AIS) and Glasgow Coma Scale (GCS). The association between the peak level of sCD163 with 1-year all-cause mortality was analyzed by logistic regression analysis. Median admission levels of sCD163 were higher in trauma patients than trauma controls [2.32 (IQR 1.73 to 2.86) vs. 1.92 (IQR 1.41 to 2.51) mg/L, p < 0.01]. Worsening GCS score was associated with a 10.3% (95% CI: 17.0 to 3.1, p < 0.01) increase in sCD163. Increasing Head-AIS score was associated with a 5.1% (95% CI: -0.5 to 11.0, p = 0.07) increase in sCD163. The remaining AIS scores and ISS were not consistently associated with sCD163 admission levels. Each mg/L increase in sCD163 peak level had an odds ratio 1.34 (95%CI: 0.98 to 1.83), p = 0.06) after adjustment for age, sex, and GCS. Circulating sCD163 is increased in traumatized patients and associated with worsening GCS. Our findings suggest an association between circulating sCD163 levels with 1-year all-cause mortality. |
